Pharmaceuticals

CHENGDA PHARMA

CHENGDA PHARMA released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 128.24 M, actual EPS CNY 0.0462

CHENGDA PHARMA released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 121.28 M, actual EPS CNY -0.1893

CHENGDA PHARMA released FY2025 Annual Earnings on April 27 After-Market BJT, actual revenue CNY 406.37 M, actual EPS CNY -0.0787

CHENGDA PHARMA FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

CHENGDA PHARMA to Release FY2025 Earnings on April 28 After-Market (BJT)

CHENGDA PHARMA released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 102.64 M, actual EPS CNY 0.026

CHENGDA PHARMA released FY2025 9 Months earnings on October 27 After-Market BJT, actual revenue CNY 285.09 M, actual EPS CNY 0.1112

CHENGDA PHARMA FY2025 Q3 Earnings Release on October 28, 2025, After-Market (BJT)

CHENGDA PHARMA released FY2025 Q2 earnings on August 25 After-Market BJT, actual revenue CNY 106.15 M, actual EPS CNY 0.0944

CHENGDA PHARMA released FY2025 Semi-Annual earnings on August 25, After-Market BJT, with actual revenue of CNY 182.45 M and EPS of CNY 0.0847

CHENGDA PHARMA to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Chengda Pharmaceutical Secretary Responds to Advantages and Investment Projects in Pharmaceutical Sector

Chengda Pharmaceutical Receives BBB ESG Rating from Huazheng Index

Shareholder Qianhai Shengtai Sold 1.15% Shares of Chengda Pharmaceutical

Major Shareholder of Chengda Pharmaceutical Reduces Shares by 1.0277%

SHAREHOLDER PLANS TO SELL STOCK OF CHENGDA PHARMACEUTICAL

Chengda Pharmaceutical Reports a Net Loss of 1.4 Million Yuan in Q1 2025

CHENGDA PHARMA released FY2024 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 89.36 M, actual EPS CNY -0.4524

CHENGDA PHARMA released FY2024 annual earnings on April 24 After-Market BJT, actual revenue CNY 333.13 M, actual EPS CNY -0.1849

CHENGDA PHARMA released FY2025 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 76.31 M, actual EPS CNY -0.0092

000001

301201

399001

603773

600707

399006

688553

002962

At the midday close on April 9, the SSE Index fell 0.73%, the Shenzhen Index dropped 0.31%, and the ChiNext decreased by 0.67%. The market opened lower and fluctuated in the morning, with computing power hardware stocks performing strongly; CDD, W-OLF TECH, WG Tech, and others hit their daily limits. Pharmaceutical stocks retreated, with CHENGDA PHARMA and HUIYU PHARMACEUTICAL falling by more than 10%. Overall, declining stocks outnumbered gainers, with approximately 4,400 stocks falling across the Shanghai, Shenzhen, and Beijing markets. Morning turnover reached 1.43 trillion yuan

Wallstreetcn

SSE Index

Shenzhen Index

WG Tech

ChiNext

HUIYU PHARMACEUTICAL

W-OLF TECH

Midday Market Review on April 9: SSE Index Drops 0.73% in Half-Day, Computing Power Hardware Stocks Strengthen Against the Trend

36Kr learned that CHENGDA PHARMA announced that the board meeting agreed to elect Ge Jianli as the chairman of the company and the director representing the company's executive affairs, agreed to appoint Lu Gang as the general manager, and appointed Peng Zhiyong, Huang Honglin, Lu Jin, Yang Xiaojing, Hu Bao, and Zhao Minwei as deputy general managers, and appointed Fei Chao as the financial director

36Kr

CHENGDA PHARMA: Elected Ge Jianli as Chairman

CHENGDA PHARMA released its third-quarter report for 2025, with operating revenue of 285 million yuan in the first three quarters, a year-on-year increase of 16.95%. The net profit attributable to the parent company was 16.7733 million yuan, a year-on-year decrease of 58.47%; the net profit after deducting non-recurring gains and losses was 3.9025 million yuan, a year-on-year decrease of 72.96%. The basic earnings per share were 0.1107 yuan

Zhitong

CHENGDA PHARMA released its performance for the first three quarters, with a net profit attributable to the parent company of 16.7733 million yuan, a decrease of 58.47%

CHENGDA PHARMA announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings by no more than 7.27%, approximately 11.0069 million shares, through centralized bidding or block trading from September 29, 2025, to December 28, 2025, within a 3-month period

CHENGDA PHARMA: Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) plans to reduce its holdings by no more than 7.27%

Recently, Chengdu Shibeikang Biopharmaceutical Technology Co., Ltd. announced the completion of its Series B financing. This round of financing was exclusively strategically invested by the listed company CHENGDA PHARMA. The funds raised will mainly be used to accelerate the construction of the R&D pipeline, expand the R&D laboratory, and promote the international application process of core products. According to Shibeikang, in its early entrepreneurial stage, it also received investments from industrial investors such as Fosun Pharma and Chuan Chuang Investment, as well as local investment institutions

Shibeikang announced the completion of Series B financing, with listed company CHENGDA PHARMA as the exclusive strategic investor

CHENGDA PHARMA released its semi-annual report for 2025, with operating revenue of 182 million yuan, a year-on-year increase of 11.24%. However, the net profit attributable to shareholders of the listed company was 12.8244 million yuan, a year-on-year decrease of 49.06%. The net profit after deducting non-recurring gains and losses was 2.899 million yuan, a year-on-year decrease of 8.37%. The basic earnings per share were 0.0847 yuan

CHENGDA PHARMA released its performance for the first half of the year, with a net profit attributable to the parent company of 12.8244 million yuan, a year-on-year decrease of 49.06%

688222

HitGen and CHENGDA PHARMA both rose over 10%, while Baiotai, Sai Sheng Pharmaceutical, Livzon Pharmaceutical, Hitec Biopharma, Chenxin Pharmaceutical, and Jiankangyuan among others rose over 5%

HitGen

Innovative drug concept stocks are repeatedly active, HitGen and CHENGDA PHARMA both rise over 10%

According to the Zhitong Finance APP, CHENGDA PHARMA announced that its shareholder Qianhai Shengtai will reduce its holdings of the company's shares by a total of 1.772 million shares through block trading from June 18, 2025, to June 24, 2025, accounting for 1.15% of the company's total share capital

CHENGDA PHARMA was reduced by 1.15% of its shares by shareholder Qianhai Shengtai

According to the Zhitong Finance APP, CHENGDA PHARMA announced that its shareholder Shenzhen Qianhai Shengtai Investment Enterprise (Limited Partnership) (referred to as "Qianhai Shengtai") plans to reduce its holdings of the company's shares through block trading by no more than 4.8949 million shares (accounting for 3.23% of the total share capital after excluding the shares in the repurchase special account) within three months from the 15 trading days following the disclosure of this announcement (from May 30, 2025, to August 29, 2025)

CHENGDA PHARMA's shareholder Qianhai Shengtai plans to reduce its holdings by no more than 3.23%

According to the Zhitong Finance APP, CHENGDA PHARMA released its first-quarter report for 2025, reporting an operating income of 76.3078 million yuan, a year-on-year decrease of 24.37%. The net loss attributable to shareholders of the listed company was 1.4 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 5.8541 million yuan. The basic loss per share was 0.0092 yuan

CHENGDA PHARMA released its first-quarter performance, turning from profit to a loss of 1.4 million yuan

CHENGDA PHARMA(301201.SZ)